Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: Dr Mazzone and colleagues1 showed that pioglitazone slowed progression of CIMT compared with glimepiride in patients with type 2 diabetes. The absolute change of CIMT was used as the primary end point instead of the number of cardiovascular events because CIMT is strongly associated with risk of future cardiovascular events.2
Kida Y, Sato T. Pioglitazone vs Glimepiride and Carotid Intima-Media Thickness. JAMA. 2007;297(12):1315-1317. doi:10.1001/jama.297.12.1316-a